We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
08:00 AM
-
Workshop Room60 mins
- Investment Summit
09:00 AM
-
Workshop Room15 mins
- Investment Summit
Setting the context, where the CGT investment landscape stands in 2026, what has changed and what it means for European therapeutic developers today Where are we in the market cycle? interpreting reco ...
09:15 AM
-
Workshop Room40 mins
- Investment Summit
Story-driven investing is over, what does evidence driven investing actually demand from founders? From narrative to proof: why scientific promise alone no longer closes rounds, and what constitutes a ...
09:55 AM
-
Workshop Room40 mins
- Investment Summit
Traditional venture capital is growing more selective and early-stage biotech are sourcing other routes of funding to progress their pipelines. Explore how alternative funding models are evolving to s ...
10:35 AM
-
Workshop Room15 mins
- Investment Summit
10:50 AM
-
Workshop Room40 mins
- Investment Summit
As the cell and gene therapy industry becomes increasingly crowded, differentiation has become a non-negotiable for securing investment. With multiple companies pursuing similar approaches, investors ...
11:30 AM
-
Workshop Room30 mins
- Investment Summit
Bringing together investor and founder who have successfully navigated the process to share practical insights on what it takes to secure capital in today’s environment. The 2026 investment checklist: ...
12:00 PM
-
Workshop Room60 mins
- Investment Summit
- Women in Advanced Therapies Congress
01:00 PM
-
Workshop Room5 mins
- Women in Advanced Therapies Congress
01:05 PM
-
Workshop Room20 mins
- Women in Advanced Therapies Congress
After years of discussion around bias, barriers, and representation, the question remains: what is actually changing and what isn’t? This candid opening session sets the tone for WiAT by shifting the ...
01:25 PM
-
Workshop Room30 mins
- Women in Advanced Therapies Congress
What does success actually look like and how do you get there? In this session, leaders share honest, experience-based insights into building careers, securing investment, and navigating pivotal trans ...Speakers
01:55 PM
-
Theatres 1 & 260 minsFocus: refine how you present your experience, expertise, and ambition
-
Theatre 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
Focus: investor decision-making and barriers in capital allocation -
Theatre 1&260 mins
- Women in Advanced Therapies Congress
- Roundtable
Focus: progression into senior roles in pharma, biotech, and startups -
60 mins
- Women in Advanced Therapies Congress
- Roundtable
Focus: the operational reality of building companies and careers in CGT/biotech -
60 mins
- Women in Advanced Therapies Congress
- Workshop
This highly interactive session connects participants with experienced professionals for focused, small-group discussions. Designed to go beyond informal advice, each interaction is structured around real challenges and actionable guidance.
-
Theatres 1 & 260 mins
- Women in Advanced Therapies Congress
- Workshop
Networking is often cited as critical but rarely taught. This session breaks down how to build and use networks with intention, particularly in an industry where access is uneven. Participants will map their current network, identify gaps, and define targeted actions to build meaningful, opportunity-driven connections.
02:55 PM
-
Workshop Room30 mins
- Women in Advanced Therapies Congress
03:25 PM
-
Workshop Room30 mins
- Women in Advanced Therapies Congress
Participants bring real challenges, from accessing funding to building teams or navigating leadership barriers, and the panel works through them live. Rather than discussing general trends, this sessi ...
03:55 PM
-
Workshop Room20 mins
- Women in Advanced Therapies Congress
The value of WiAT lies in the people in the room, but too often, that potential goes untapped. This speed networking session is designed to actively surface expertise, experience, and opportunities ac ...
04:15 PM
-
Workshop Room5 mins
- Women in Advanced Therapies Congress
04:30 PM
-
Theatre 290 minsOur annual kick-off welcome party takes place against the backdrop of the beautiful Barcelona skyline!
09:00 AM
-
Theatre 1&25 mins
- Plenary
09:05 AM
-
Theatre 1&240 mins
- Plenary
From legislation to execution: What ATMP developers must change now in regulatory, CMC and evidence planning to stay aligned with EU reform over the next 12 months. Fixing fragmentation where it hurts ...
09:45 AM
-
Theatre 1&235 mins
- Plenary
‘We are still waiting’: What patients and caregivers across Europe experience today - from diagnosis delays to eligibility dead-ends and why ATMP access remains inconsistent despite scientific progres ...
10:20 AM
-
Theatre 1&240 mins
- Plenary
Speed breaks first: Why Europe still loses ATMP programmes at the trial-start and scale-up stages and what can be fixed in the next 12 months around approvals, site readiness and cross-border trial ex ...
11:00 AM
-
Exhibition Hall30 mins
- Networking Break
11:30 AM
-
Theatre 115 mins
- Cell & Gene Therapy Clinical Pathways
-
Spotlight: In vivo by design: What had to change to move from promise to predictable clinical signalTheatre 215 mins
- Operational & Commercial Performance
The early in vivo reality check: What initially limited delivery, expression or safety—and how those constraints forced changes in platform design, dosing strategy or target selection. From isolated s ...
11:45 AM
-
Theatre 115 mins
- Cell & Gene Therapy Clinical Pathways
Proof isn’t the problem progress is: Why even well-validated CGT programmes (including late-stage assets) still stall between Phase I and II, and how trial infrastructure, not science, is increasingly ... -
Theatre 215 mins
- Operational & Commercial Performance
Biology isn’t the only limiter anymore: As in vivo programmes advance, why delivery consistency, biodistribution insight and execution infrastructure are becoming the real differentiators. Where momen ...
12:00 PM
-
Theatre 130 mins
- Cell & Gene Therapy Clinical Pathways
A view on the latest clinical trials, innovations and trends coming out of Europe, US and further afield and what practical coordination would make cross-border trials, faster, simpler and more attrac ... -
Theatre 230 mins
- Operational & Commercial Performance
The inflection is measurable: What recent in vivo clinical readouts are showing about delivery efficiency, expression control and safety—and where performance is becoming reproducible rather than exce ...
12:30 PM
-
Exhibition Hall75 mins
- Networking Break
01:45 PM
-
Theatre 115 mins
- Cell & Gene Therapy Clinical Pathways
Early success doesn’t scale by default: Where AAV production processes that worked in preclinical and early clinical settings failed under scale, consistency or regulatory scrutiny and why assumptions ... -
Theatre 230 mins
- Operational & Commercial Performance
Session Overview Advanced therapies are stretching not just science and regulation but the very design of capital itself. Across Europe, a growing sentiment has emerged that traditional venture capita ...
02:00 PM
-
Theatre 115 mins
- Cell & Gene Therapy Clinical Pathways
Why scaling AAV is still hard: The recurring technical bottlenecks seen across programmes—spanning upstream productivity, downstream resolution, analytics and batch-to-batch variability. Manufacturing ...
02:15 PM
-
Theatre 130 mins
- Cell & Gene Therapy Clinical Pathways
AAV demand has outpaced infrastructure: Why current production models struggle to meet clinical and commercial demand and which upstream, downstream and process innovations are finally closing the eff ... -
Theatre 230 mins
- Operational & Commercial Performance
02:45 PM
-
Theatre 130 mins
- Cell & Gene Therapy Clinical Pathways
Efficacy data as a scaling input, not an endpoint: How Phase I expansion and Phase II data should actively inform tech transfer, manufacturing readiness and comparability so scale-up and fundraising d ... -
Theatre 215 mins
- Operational & Commercial Performance
Why the old production model breaks: What Roche learned about the limits of legacy CGT manufacturing cost, throughput, flexibility and why incremental upgrades were no longer enough. Inside Penzberg: ...
03:00 PM
-
Theatre 215 mins
- Operational & Commercial Performance
Capacity solved, complexity exposed: Why increasing CGT manufacturing capacity alone doesn’t unlock commercial success and how variability, flexibility and operational friction now limit real-world ad ...
03:15 PM
-
Theatre 130 mins
- Cell & Gene Therapy Clinical Pathways
Submission-ready’ is not ‘FDA-ready’: What the FDA expects to see in a BLA beyond what typically satisfies EMA or national authorities and where European teams most often underestimate depth across CM ... -
Theatre 230 mins
- Operational & Commercial Performance
03:45 PM
-
Exhibition Hall30 mins
04:15 PM
-
Workshop Room60 mins
- Roundtable
-
Workshop Room60 mins
- Roundtable
Chairperson -
Workshop Room60 mins
- Roundtable
-
Workshop Room60 mins
- Roundtable
-
Workshop Room60 mins
- Roundtable
-
Workshop Room60 mins
- Roundtable
Chairperson -
Workshop Room60 mins
- Roundtable
Chairperson -
Workshop Room60 mins
- Roundtable
-
Workshop Room60 mins
- Roundtable
-
Workshop Room60 mins
- Roundtable
-
Workshop Room60 mins
- Roundtable
05:45 PM
-
Exhibition Hall105 mins
- Networking Break
09:00 AM
-
Theatre 1&290 mins
- Plenary
Join us for an exciting session where innovative biotech start-ups pitch their groundbreaking ideas and solutions. Watch as they present to a panel of expert investors, who will provide real-time feed ...
10:30 AM
-
Theatre 1&245 mins
- Plenary
From optional to inevitable: Where agentic and analytical AI are already changing discovery and early CGT development and what must be true for AI to become a trusted, default tool rather than a pilot ...Speakers
11:15 AM
-
Exhibition Hall30 mins
- Networking Break
11:45 AM
-
Theatre 115 mins
- Cell & Gene Therapy Clinical Pathways
Remission without bespoke manufacturing: What recent European clinical results in aggressive leukaemias show about the true potential of off-the-shelf CAR-T and NK therapies and how this changes assum ... -
Theatre 215 mins
- Operational & Commercial Performance
The uncomfortable truth: Where early CMC and manufacturing assumptions quietly inflated cost of goods as programmes moved toward later-stage development and why these issues only surfaced under scale ...
12:00 PM
-
Theatre 115 mins
- Cell & Gene Therapy Clinical Pathways
Hospitals are the bottleneck and the solution: Why even off-the-shelf cell therapies fail without hospital integration and what practical delivery models are emerging across Europe. Designing delivery ... -
Theatre 215 mins
- Operational & Commercial Performance
Why COGS stays stubbornly high: The recurring technical and operational drivers of cost across CGT programme from starting materials and batch failure rates to logistics and facility utilisation. Wher ...
12:15 PM
-
Theatre 130 mins
- Cell & Gene Therapy Clinical Pathways
Understanding the AGORA model: How collaborative, hospital-anchored models like AGORA are reshaping access to gene and cell therapies for rare and ultra-rare diseases. We cannot scale without hospital ... -
Theatre 230 mins
- Operational & Commercial Performance
The cost equation is breaking :Are allogeneic therapies genuinely approaching a manufacturing inflection point and if so, what does that mean for the long-term viability of autologous models that stil ...
12:45 PM
-
Exhibition Hall75 mins
- Networking Break
02:00 PM
-
Theatre 1&215 mins
- Plenary
02:15 PM
-
Theatre 1&230 mins
- Plenary
What it takes to build a decentralised CAR-T manufacturing model in practice, and where the original “point-of-care” vision met operational reality. Key lessons from running multi-site GMP manufacturi ...
02:45 PM
-
Theatre 1&245 mins
- Plenary
The next modality frontier is not guaranteed: Which modalities are genuinely emerging as the next growth engines, whether cell therapies face structural headwinds or reinvention, and what lessons Euro ...